You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The combined solution will give health systems access to real-time genetics expertise so they can integrate genetic test results into patients' care.
Through this partnership, the companies hope to help oncologists make better testing and treatment decisions, as well as improve clinical trial matching.
With its recent $50 million VC round, the British bioinformatics firm is targeting growth in new applications as it accelerates tertiary data analysis.
The British bioinformatics firm expects to move into somatic cancer and wellness programs, as well as widen its geographic footprint.
The startup has launched oncology and pulmonology beta tests at five US health systems, with help from precision health firm mProbe and several pharma partners.
The Swiss-American bioinformatics company touts its networks of multimodal data and numerous partnerships as it looks to support "data-driven medicine."
With $6.5M in new funding, the Israeli bioinformatics startup is looking to open a US office as it builds relationships with pharma, cancer centers, and payors.
In the next round of the eMERGE program, NIH is supporting development of methodologies for integrating genotypic and phenotypic risk scoring into clinical care.
The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.
Ten sites across the US will seek to integrate genomic risk assessment into clinical care, with a focus on diverse populations.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.